早期与晚期使用巴姆兰尼韦单抗对高风险COVID-19患者再入院的影响
本研究为IRB批准的回顾性评估,纳入急诊科按EUA标准接受巴姆兰尼韦单抗的成人COVID-19患者839例,按症状≤3天(早期)与4-10天(晚期)分组。主要终点28天COVID相关住院率两组无差异(7.5% vs 8.2%,p=0.71),28天COVID相关急诊就诊率两组亦无差异(13%患者返回急诊)。结论提示在症状出现前3天与第4-10天给药,28天住院率无差异,需前瞻性研究进一步明确可能获益的患者特征。
要点
- 839例急诊成人COVID-19患者按EUA标准接受巴姆兰尼韦单抗,早期组(症状≤3天)与晚期组(4-10天)28天COVID相关住院率无差异(7.5% vs 8.2%,p=0.71)。
- 28天COVID相关急诊就诊率两组无差异,13%患者返回急诊。
- 研究为单中心回顾性评估,结果不能推断巴姆兰尼韦单抗在任一 timing 的疗效优劣。
- 原文未提及医院及ICU住院时长、院内死亡率的组间比较结果。
- 作者结论:需前瞻性研究扩展可能从单克隆抗体治疗中获益或不获益的患者特征。
适用人群与场景
- 急诊科成人COVID-19阳性患者,按EUA标准接受巴姆兰尼韦单抗治疗。
- 按症状出现时间分为早期(≤3天)与晚期(4-10天)两组。
诊断标准与关键阈值
- 分组依据:症状出现≤3天为早期,4-10天为晚期。
处置流程与药物剂量
- 原文未提及巴姆兰尼韦单抗的具体剂量、给药途径、频次或疗程。
- 原文提及按EUA标准在急诊科给予巴姆兰尼韦单抗,症状出现至给药时间在10天以内。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:IRB批准的回顾性评估;样本量839例成人急诊患者;单中心(原文未明确中心数,仅提及急诊科)。
- 干预:巴姆兰尼韦单抗按EUA标准给药;对照:早期(症状≤3天) vs 晚期(4-10天)。
- 主要终点:28天COVID相关住院率(或治疗失败),早期组7.5% vs 晚期组8.2%,p=0.71,无差异。
- 次要终点:28天COVID相关急诊就诊率两组无差异,13%患者返回急诊;原文未提及医院及ICU住院时长、院内死亡率的组间比较数值。
证据类型、等级与局限
- 证据类型:回顾性队列研究(单中心、IRB批准)。
- 局限:回顾性设计、单中心、样本量839例、未提及盲法或混杂控制;作者指出需前瞻性研究验证。
对床旁实践的改变
- 对于急诊高风险COVID-19患者,在症状出现前3天或第4-10天给予巴姆兰尼韦单抗,28天COVID相关住院率无差异,不支持仅因给药时间较早或较晚而改变用药决策。
- 研究为回顾性单中心评估,不能据此推广为巴姆兰尼韦单抗在所有时间窗均等效的结论。
- 原文未提及适用或不适用人群的进一步限定,临床决策仍需结合EUA标准及个体情况。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Recombinant monoclonal antibody therapies have been utilized under emergency use authorization (EUA) for the prevention of clinical decompensation in high-risk COVID-19 positive patients for up to 10 days from symptom onset. The purpose of this study was to determine the impact of the timing of the monoclonal antibody, bamlanivimab, on clinical outcomes in high-risk COVID-19 positive patients.
METHODS: This was an IRB-approved, retrospective evaluation of adult patients who received bamlanivimab per EUA criteria in the emergency department (ED). Patients were dichotomized into two groups- 3 days of symptoms or less (early) versus 4 to 10 days (late). The primary outcome was hospitalization for COVID-related illness at 28 days (or treatment failure). Secondary outcomes were COVID-related ED visits at 28 days, hospital and intensive care unit (ICU) length of stay (LOS), and in-hospital mortality at 28 days.
RESULTS: A total of 839 patients were included in the analysis. There was no difference observed in COVID-related hospitalization rates within 28 days between the early and late bamlanivimab administration groups (7.5% vs. 8.2%, p = 0.71). There was no difference in COVID-related ED visits within 28 days with 13% of patients returning to the ED.
CONCLUSIONS: In conclusion, there were no differences in the rates of hospitalization at 28 days when bamlanivimab was administered in the first 3 days of illness versus days 4 to 10. Future prospective studies are warranted to expand upon the characteristics of patients that may or may not benefit from monoclonal antibody therapy.
参考来源
- Melton JD, Wilson K, Blind F, et al. Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19. Am J Emerg Med. 2021. PMID: 34487951. doi:10.1016/j.ajem.2021.08.032
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。